search
Back to results

Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections (DoSe iT)

Primary Purpose

Otitis Media, Tonsillitis, Pharyngitis

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Clarithromycin DST (125 mg)
Clarithromycin DST (187.5 mg)
Clarithromycin DST (250 mg)
Clarithromycin Syrup (125 mg)
Clarithromycin Syrup (187.5 mg)
Clarithromycin Syrup (250 mg)
Sponsored by
Grünenthal GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Otitis Media

Eligibility Criteria

2 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female children weighing 12-40 kg.
  • Age 2 -12 years.
  • Written informed consent (parents).
  • Diagnosis of acute otitis media, tonsillitis, pharyngitis, or acute bacterial bronchitis requiring antibiotic treatment.

Exclusion Criteria:

  • Participation in another study of investigational products or of devices parallel to, or less than 4 weeks before study entry, or previous participation in this study (for safety reasons).
  • Known to or suspected of not being able to comply with the study protocol and the use of clarithromycin.
  • Requirement for, or current use of, systemic antibacterial agents not specified in the protocol.
  • Necessity of dose reduction due to any concomitant disease.
  • Known human immunodeficiency virus (HIV) positive.
  • Other inflammatory/infectious diseases of the ear, the upper respiratory tract or the nose and throat.
  • History or presence of disease or concomitant medication contraindicating the use of clarithromycin.
  • Known or suspected intolerance / hypersensitivity to macrolides.
  • Contraindications according to the clarithromycin Summary of Product Characteristics (SmPC).
  • Indication for antibiotic treatment for less than 7 days or more than 10 days.
  • If known before entry, bacterial isolate resistant to clarithromycin.

Sites / Locations

  • DE11
  • DE10
  • DE09
  • DE08
  • DE12
  • DE14
  • DE05
  • DE06
  • DE03
  • DE02
  • DE13
  • DE04
  • DE07
  • DE01
  • PL03
  • PL06
  • PL01
  • PL04
  • PL05
  • PL02

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Clarithromycin DST

Clarithromycin Syrup

Arm Description

Participants received oral administration of Clarithromycin DST twice a day: 125.0 mg straw, participants with body weight between 12 and 19 kg (approximate age 2-4 years). 187.5 mg straw, participants with body weight between 20 and 29 kg (approximate age 4-8 years). 250.0 mg straw, participants with body weight between 30 and 40 kg (approximate age 8-12 years). For oral intake of DST granules, the lower end of the straw was to be dipped into a glass with a clear, cool or lukewarm, preferably flavored beverage of participant choice. Suitable beverages were lemonade (carbonated or not), clear fruit juices without pulp, tea or water. The beverage was to be sipped smoothly through the straw.

Participants received oral administration of Clarithromycin Syrup twice a day: 2.5 ml (125 mg) participants with body weight between 12 and 19 kg (approximate age 2-4 years). 3.75 ml (187.5 mg) participants with body weight between 20 and 29 kg (approximate age 4-8 years). 5 ml (250 mg) participants with body weight between 30 and 40 kg (approximate age 8-12 years).

Outcomes

Primary Outcome Measures

Preparation of the medication (during treatment)
This was analyzed by a Parents' Questionnaire by means of the question "How was the preparation of the medication?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.
Preparation of the medication (after treatment)
This was analyzed by a Parents' Questionnaire by means of the question "How was the preparation of the medication?". Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.
Dosing accuracy (during treatment)
This was analyzed by a Parents' Questionnaire by means of the question "How do you rate giving the right dose?". Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very simple", "simple", "difficult" and "very difficult". The best outcome was "very simple", the worst "very difficult". The percentage of responses for each of the possible answers was calculated.
Dosing accuracy (after treatment)
This was analyzed by a Parents' Questionnaire by means of the question "How do you rate giving the right dose?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very simple", "simple", "difficult" and "very difficult". The best outcome was "very simple", the worst "very difficult". The percentage of responses for each of the possible answers was calculated.
Handling of the medication (during treatment)
This was analyzed by a Parents' Questionnaire by means of the question "How satisfied are you with the handling of the medication?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very satisfied", "satisfied", "less satisfied" and "not satisfied". The best outcome was "very satisfied", the worst "not satisfied". The percentage of responses for each of the possible answers was calculated.
Handling of the medication (after treatment)
This was analyzed by a Parents' Questionnaire by means of the question "How satisfied are you with the handling of the medication?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very satisfied", "satisfied", "less satisfied" and "not satisfied". The best outcome was "very satisfied", the worst "not satisfied". The percentage of responses for each of the possible answers was calculated.
Administration of the medication (during treatment)
This was analyzed by a Parents' Questionnaire by means of the question "How do you judge the administration of the medication?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.
Administration of the medication (after treatment)
This was analyzed by a Parents' Questionnaire by means of the question "How do you judge the administration of the medication?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.
Ease to follow the prescribed dosing schedule (during treatment)
This was analyzed by a Parents' Questionnaire by means of the question "How easy is it to follow the dosing schedule?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.
Ease to follow the prescribed dosing schedule (after treatment)
This was analyzed by a Parents' Questionnaire by means of the question "How easy is it to follow the dosing schedule?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.
Child's feeling about the taste of the medication (during treatment)
This was analyzed by a Parents' Questionnaire by means of the question "What does your child feel about the taste of the medication?". Possible answers (tick one only) were "very good", "good", "acceptable", "bad", "very bad" and "no comment". The best outcome was "very good", the worst "very bad". The percentage of responses for each of the possible answers was calculated.
Child's feeling about the taste of the medication (after treatment)
This was analyzed by a Parents' Questionnaire by means of the question "What does your child feel about the taste of the medication?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very good", "good", "acceptable", "bad", "very bad" and "no comment". The best outcome was "very good", the worst "very bad". The percentage of responses for each of the possible answers was calculated.
Child's feeling about aftertaste of the medication (during treatment)
This was analyzed by a Parents' Questionnaire by means of the question "What does your child feel about the aftertaste of the medication?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very good", "good", "acceptable", "bad", "very bad" and "no comment". The best outcome was "very good", the worst "very bad". The percentage of responses for each of the possible answers was calculated.
Child's feeling about the aftertaste of the medication (after treatment)
This was analyzed by a Parents' Questionnaire by means of the question "What does your child feel about the aftertaste of the medication?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very good", "good", "acceptable", "bad", "very bad" and "no comment". The best outcome was "very good", the worst "very bad". The percentage of responses for each of the possible answers was calculated.
Optimal administration form
This was analyzed by a Parents' Questionnaire by means of the question "Do you think the administration form is optimal for your child?". Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "Yes", "No", and "Do not know". The percentage of responses for each of the possible answers was calculated.
Treatment preference
Treatment preference was analyzed by a Parents' Questionnaire by means of the question "Would you or your child prefer this administration form next time?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "Yes" and "No". The percentage of responses for each of the possible answers was calculated.
Treatment adherence
The child's adherence to the prescribed course of therapy was checked by determining the number of unused straws or the residual volume in the medication bottles, respectively, when unused study medication was returned to the site on Day 11, 12, 13, or 14. A participant was considered to be: Fully treatment adherent: >90 % of prescribed doses taken within the prescribed course of therapy. Partially treatment adherent: 70-90% of prescribed doses taken within the prescribed course of therapy. Non adherent: Omission of 2 or more consecutive doses or <70% of prescribed doses taken within the prescribed course of therapy. The percentage of participants in each of the 3 categories was calculated.

Secondary Outcome Measures

Child's Health Status compared to Baseline (during treatment)
The participant's overall health status compared to baseline (= acute infection requiring antibiotic treatment) was assessed by the investigator as "cured", "improved", "no changes", or "deteriorated". The clinical assessment was made during a phone interview with the parent/caregiver on either Day 3, 4, or 5. The best outcome was "cured", the worst was "deteriorated". The percentage of participants per outcome category was calculated.
Child's Health Status compared to Baseline (after treatment)
The participant's overall health status compared to baseline (= acute infection requiring antibiotic treatment) was assessed by the investigator as "cured", "improved", "no changes", or "deteriorated". The clinical assessment was made once at a site visit on either Day 11, 12, 13. or 14. The best outcome was "cured", the worst was "deteriorated". The percentage of participants per outcome category was calculated.

Full Information

First Posted
June 5, 2019
Last Updated
July 10, 2019
Sponsor
Grünenthal GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT04016051
Brief Title
Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections
Acronym
DoSe iT
Official Title
Comparison of Treatment Satisfaction and Treatment Adherence of a Novel Application Form "Dose Sipping Technology" (DST) of Oral Clarithromycin vs. Clarithromycin Syrup in Children Suffering From Acute Otitis Media, Tonsillitis, Pharyngitis, or Acute Bacterial Bronchitis (DoSe iT)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
September 22, 2004 (Actual)
Primary Completion Date
December 23, 2004 (Actual)
Study Completion Date
December 23, 2004 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Grünenthal GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study was performed in children with upper respiratory tract infections (acute ear infection, infection of the tonsils or throat, or bacterial inflammation of the bronchi) who needed treatment with an antibiotic (clarithromycin). The study investigated a new technology which delivers the antibiotic in a straw (dose sipping technology, DST) in comparison to a marketed syrup.
Detailed Description
The study population were children aged 2-12 years (weight 12-40 kg) suffering from upper respiratory tract infections (acute otitis media, tonsillitis, pharyngitis, or acute bacterial bronchitis) and who needed antibiotic treatment. The study compared treatment satisfaction and treatment adherence of oral clarithromycin DST (125 mg, 187.5 mg, or 250 mg twice daily) with the established oral clarithromycin syrup administered via a graduated syringe (Klacid Syrup Forte®, 250 mg/5mL) at the same fixed daily doses. Fixed doses of 125 mg, 187.5 mg and 250 mg of clarithromycin DST offer the pediatrician the flexibility to treat children of different body weight and age adequately at the recommended daily dose of 15 (12.5-20) mg/kg. All children were treated for 7 to 10 day (14 to 20 doses). Treatment satisfaction by the guardian/caregiver in terms of handling and administration of the clarithromycin DST straw and the comparator clarithromycin syrup, convenience of the administration, acceptance of taste and aftertaste, and treatment satisfaction with respect to future use was evaluated by means of a Parents' Questionnaire once on either Day 3, 4, or 5 and once on either Day 11, 12, 13, or 14. In addition, treatment adherence/willingness of medication intake and the child's health status were assessed. The safety program comprised recording and evaluation of adverse events and countermeasures.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Otitis Media, Tonsillitis, Pharyngitis, Bronchitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
265 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Clarithromycin DST
Arm Type
Experimental
Arm Description
Participants received oral administration of Clarithromycin DST twice a day: 125.0 mg straw, participants with body weight between 12 and 19 kg (approximate age 2-4 years). 187.5 mg straw, participants with body weight between 20 and 29 kg (approximate age 4-8 years). 250.0 mg straw, participants with body weight between 30 and 40 kg (approximate age 8-12 years). For oral intake of DST granules, the lower end of the straw was to be dipped into a glass with a clear, cool or lukewarm, preferably flavored beverage of participant choice. Suitable beverages were lemonade (carbonated or not), clear fruit juices without pulp, tea or water. The beverage was to be sipped smoothly through the straw.
Arm Title
Clarithromycin Syrup
Arm Type
Active Comparator
Arm Description
Participants received oral administration of Clarithromycin Syrup twice a day: 2.5 ml (125 mg) participants with body weight between 12 and 19 kg (approximate age 2-4 years). 3.75 ml (187.5 mg) participants with body weight between 20 and 29 kg (approximate age 4-8 years). 5 ml (250 mg) participants with body weight between 30 and 40 kg (approximate age 8-12 years).
Intervention Type
Drug
Intervention Name(s)
Clarithromycin DST (125 mg)
Intervention Description
Clarithromycin DST (125.0 mg clarithromycin / straw).
Intervention Type
Drug
Intervention Name(s)
Clarithromycin DST (187.5 mg)
Intervention Description
Clarithromycin DST (187.5 mg clarithromycin / straw).
Intervention Type
Drug
Intervention Name(s)
Clarithromycin DST (250 mg)
Intervention Description
Clarithromycin DST (250.0 mg clarithromycin / straw).
Intervention Type
Drug
Intervention Name(s)
Clarithromycin Syrup (125 mg)
Other Intervention Name(s)
Klacid Syrup® Forte 250 mg/5mL
Intervention Description
Clarithromycin Syrup 2.5 ml (125 mg).
Intervention Type
Drug
Intervention Name(s)
Clarithromycin Syrup (187.5 mg)
Other Intervention Name(s)
Klacid Syrup® Forte 250 mg/5mL
Intervention Description
Clarithromycin Syrup 3.75 ml (187.5 mg).
Intervention Type
Drug
Intervention Name(s)
Clarithromycin Syrup (250 mg)
Other Intervention Name(s)
Klacid Syrup® Forte 250 mg/5mL
Intervention Description
Clarithromycin Syrup 5 ml (250 mg).
Primary Outcome Measure Information:
Title
Preparation of the medication (during treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "How was the preparation of the medication?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 3-5
Title
Preparation of the medication (after treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "How was the preparation of the medication?". Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 11-14
Title
Dosing accuracy (during treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "How do you rate giving the right dose?". Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very simple", "simple", "difficult" and "very difficult". The best outcome was "very simple", the worst "very difficult". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 3-5
Title
Dosing accuracy (after treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "How do you rate giving the right dose?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very simple", "simple", "difficult" and "very difficult". The best outcome was "very simple", the worst "very difficult". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 11-14
Title
Handling of the medication (during treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "How satisfied are you with the handling of the medication?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very satisfied", "satisfied", "less satisfied" and "not satisfied". The best outcome was "very satisfied", the worst "not satisfied". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 3-5
Title
Handling of the medication (after treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "How satisfied are you with the handling of the medication?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very satisfied", "satisfied", "less satisfied" and "not satisfied". The best outcome was "very satisfied", the worst "not satisfied". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 11-14
Title
Administration of the medication (during treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "How do you judge the administration of the medication?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 3-5
Title
Administration of the medication (after treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "How do you judge the administration of the medication?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 11-14
Title
Ease to follow the prescribed dosing schedule (during treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "How easy is it to follow the dosing schedule?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 3-5
Title
Ease to follow the prescribed dosing schedule (after treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "How easy is it to follow the dosing schedule?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 11-14
Title
Child's feeling about the taste of the medication (during treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "What does your child feel about the taste of the medication?". Possible answers (tick one only) were "very good", "good", "acceptable", "bad", "very bad" and "no comment". The best outcome was "very good", the worst "very bad". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 3-5
Title
Child's feeling about the taste of the medication (after treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "What does your child feel about the taste of the medication?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very good", "good", "acceptable", "bad", "very bad" and "no comment". The best outcome was "very good", the worst "very bad". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 11-14
Title
Child's feeling about aftertaste of the medication (during treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "What does your child feel about the aftertaste of the medication?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very good", "good", "acceptable", "bad", "very bad" and "no comment". The best outcome was "very good", the worst "very bad". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 3-5
Title
Child's feeling about the aftertaste of the medication (after treatment)
Description
This was analyzed by a Parents' Questionnaire by means of the question "What does your child feel about the aftertaste of the medication?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very good", "good", "acceptable", "bad", "very bad" and "no comment". The best outcome was "very good", the worst "very bad". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 11-14
Title
Optimal administration form
Description
This was analyzed by a Parents' Questionnaire by means of the question "Do you think the administration form is optimal for your child?". Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "Yes", "No", and "Do not know". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 11-14
Title
Treatment preference
Description
Treatment preference was analyzed by a Parents' Questionnaire by means of the question "Would you or your child prefer this administration form next time?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "Yes" and "No". The percentage of responses for each of the possible answers was calculated.
Time Frame
Day 11-14
Title
Treatment adherence
Description
The child's adherence to the prescribed course of therapy was checked by determining the number of unused straws or the residual volume in the medication bottles, respectively, when unused study medication was returned to the site on Day 11, 12, 13, or 14. A participant was considered to be: Fully treatment adherent: >90 % of prescribed doses taken within the prescribed course of therapy. Partially treatment adherent: 70-90% of prescribed doses taken within the prescribed course of therapy. Non adherent: Omission of 2 or more consecutive doses or <70% of prescribed doses taken within the prescribed course of therapy. The percentage of participants in each of the 3 categories was calculated.
Time Frame
Day 11-14
Secondary Outcome Measure Information:
Title
Child's Health Status compared to Baseline (during treatment)
Description
The participant's overall health status compared to baseline (= acute infection requiring antibiotic treatment) was assessed by the investigator as "cured", "improved", "no changes", or "deteriorated". The clinical assessment was made during a phone interview with the parent/caregiver on either Day 3, 4, or 5. The best outcome was "cured", the worst was "deteriorated". The percentage of participants per outcome category was calculated.
Time Frame
Day 3-5
Title
Child's Health Status compared to Baseline (after treatment)
Description
The participant's overall health status compared to baseline (= acute infection requiring antibiotic treatment) was assessed by the investigator as "cured", "improved", "no changes", or "deteriorated". The clinical assessment was made once at a site visit on either Day 11, 12, 13. or 14. The best outcome was "cured", the worst was "deteriorated". The percentage of participants per outcome category was calculated.
Time Frame
Day 11-14

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female children weighing 12-40 kg. Age 2 -12 years. Written informed consent (parents). Diagnosis of acute otitis media, tonsillitis, pharyngitis, or acute bacterial bronchitis requiring antibiotic treatment. Exclusion Criteria: Participation in another study of investigational products or of devices parallel to, or less than 4 weeks before study entry, or previous participation in this study (for safety reasons). Known to or suspected of not being able to comply with the study protocol and the use of clarithromycin. Requirement for, or current use of, systemic antibacterial agents not specified in the protocol. Necessity of dose reduction due to any concomitant disease. Known human immunodeficiency virus (HIV) positive. Other inflammatory/infectious diseases of the ear, the upper respiratory tract or the nose and throat. History or presence of disease or concomitant medication contraindicating the use of clarithromycin. Known or suspected intolerance / hypersensitivity to macrolides. Contraindications according to the clarithromycin Summary of Product Characteristics (SmPC). Indication for antibiotic treatment for less than 7 days or more than 10 days. If known before entry, bacterial isolate resistant to clarithromycin.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Grünenthal Study Director
Organizational Affiliation
Grünenthal GmbH
Official's Role
Study Director
Facility Information:
Facility Name
DE11
City
Balve
ZIP/Postal Code
58802
Country
Germany
Facility Name
DE10
City
Beckum
ZIP/Postal Code
59269
Country
Germany
Facility Name
DE09
City
Hameln
ZIP/Postal Code
31785
Country
Germany
Facility Name
DE08
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Facility Name
DE12
City
Künzing
ZIP/Postal Code
94550
Country
Germany
Facility Name
DE14
City
München
ZIP/Postal Code
80393
Country
Germany
Facility Name
DE05
City
München
ZIP/Postal Code
81241
Country
Germany
Facility Name
DE06
City
München
ZIP/Postal Code
81543
Country
Germany
Facility Name
DE03
City
München
ZIP/Postal Code
81669
Country
Germany
Facility Name
DE02
City
München
ZIP/Postal Code
81675
Country
Germany
Facility Name
DE13
City
München
ZIP/Postal Code
81739
Country
Germany
Facility Name
DE04
City
Olching
ZIP/Postal Code
82140
Country
Germany
Facility Name
DE07
City
Pullach im Isartal
ZIP/Postal Code
82049
Country
Germany
Facility Name
DE01
City
Unterhaching
ZIP/Postal Code
82008
Country
Germany
Facility Name
PL03
City
Kozieglowy
Country
Poland
Facility Name
PL06
City
Kraków
Country
Poland
Facility Name
PL01
City
Lódz
Country
Poland
Facility Name
PL04
City
Otwock
Country
Poland
Facility Name
PL05
City
Warszawa
Country
Poland
Facility Name
PL02
City
Wroclaw
Country
Poland

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections

We'll reach out to this number within 24 hrs